Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients

Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients

Serum antibody titre against COVID-19 spike protein will be measured before, after the first dose, and after the second dose (when applicable) in cancer patients who are receiving or received anti-cancer drugs. Side effects of vaccination and actual incidence of COVID-19 will be monitored.

Inclusion Criteria:

• 20 years of age or older
• Patients who are receiving or received anti-cancer drugs
• Those who are not vaccinated against COVID-19 at the time of enrollment
• Written informed consent

Exclusion Criteria:

• Any contraindications to COVID-19 vaccines
• Those who were already vaccinated
• Those who are on immunosuppressants or infected with HIV
• Those who underwent organ transplantation
• Active infections (for example, pneumonia)